Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The main aim of this study was to compare the safety and efficacy of IR MPH administered three times daily to those of once daily OROS-MPH. METHODS: Subjects were outpatient adults satisfying full diagnostic criteria for DSM-IV ADHD between 19 and 60 years of age. Data from two independently conducted 6-week placebo controlled, randomized clinical trials of IR-MPH (tid) and of OROS-MPH were pooled to create three study groups: Placebo (N = 116), IR-MPH (tid) (N = 102) and OROS-MPH (N = 67). RESULTS: Eight-five percent (N = 99) of placebo treated subjects, 77% (N = 79) of the IR-MPH (tid) treated subjects, and 82% (N = 55) of the OROS-MPH treated subjects completed the 6-week trial. Total daily doses at endpoint were 80.9 +/- 31.9 mg, 74.8 +/- 26.2 mg, and 95.4 +/- 26.3 mg in the OROS-MPH, IR-MPH (tid), and placebo groups, respectively. At endpoint, 66% (N = 44) of subjects receiving OROS-MPH and 70% (N = 71) of subjects receiving IR-MPH (tid) were considered responders compared with 31% (N = 36) on placebo. CONCLUSION: Comparison of data from two similarly designed, large, randomized, placebo-controlled, trials, showed that equipotent daily doses of once daily OROS-MPH had similar efficacy to that of TID administered IR MPH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1792 · Cited by 950 · cited 1×
“This interview was selected because it diagnoses both lifetime and current month psychopathology and has been used extensively in clinical and research settings [11,15].”
Self-citationVariables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow, N. D., & Swanson, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1909 · Cited by 475 · cited 2×
“more gradual rise of plasma MPH concentration with the OROS formulation of MPH could lead to a slower onset of blockade of the presynaptic DAT and therefore a lower risk for detection of euphoria [22].”
Spencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402 · cited 1×
“5 mg/kg of immediate release methylphenidate (IR MPH) [5-9], clearer patterns of response were documented in studies using doses of approximately 1 mg kg of IR-MPH [10,11].”
Self-citationSpencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385 · cited 5×
“To this end we used data from two similarly designed, large, randomized, placebo-controlled, six week trials of IR and OROS-MPH in adults with DSM-IV ADHD [11,12].”
InfluentialSelf-citationGender effects on Attention-Deficit/Hyperactivity disorder in adults, revisited
Biederman, J., Faraone, S. V., Monuteaux, M. C., Bober, M., & Cadogen, E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.003 · Cited by 385 · cited 1×
“Recent work has also documented the severe functional impairments associated with ADHD including educational and occupational under attainment, driving accidents, addictive behaviors and a wide range of interpersonal deficits adversely impacting all aspects of life [4] supporting the need for the identification of saf…”
Self-citationKessler, R. C., Adler, L., Ames, M., Barkley, R. A., Birnbaum, H., Greenberg, P., Johnston, J. A., Spencer, T., & ??st??n, T. B. (2005) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000166863.33541.39 · Cited by 335
Self-citationMurphy, P., & Schachar, R. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1156 · Cited by 303 · cited 1×
“Although the usefulness of self reports of ADHD symptoms are limited in pediatric samples, there is evidence that self reports of adults with ADHD correspond very well to corroborating histories provided by parents and spouses [24].”
Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M., & Spencer, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.011 · Cited by 267
Self-citationBouffard, R., Hechtman, L., Minde, K., & Iaboni-Kassab, F. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800806 · Cited by 81 · cited 1×
“5 mg/kg of immediate release methylphenidate (IR MPH) [5-9], clearer patterns of response were documented in studies using doses of approximately 1 mg kg of IR-MPH [10,11].”
Cited by
Mick, E., Faraone, S. V., Spencer, T., Zhang, H. F., & Biederman, J. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707308468 · Cited by 95
Self-citationRamos-Quiroga, J. A., Bosch, R., Castells, X., Valero, S., Nogueira, M., Gómez, N., Yelmo, S., Ferrer, M., Martínez, Y., & Casas, M. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00005 · Cited by 54
Attention-Deficit/Hyperactivity Disorder in Adults: Evidence-Based Recommendations for Management
Rostain, A. L. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.09.1905 · Cited by 50
Casas, M., Rösler, M., Sandra Kooij, J. J., Ginsberg, Y., Ramos-Quiroga, J. A., Heger, S., Berwaerts, J., Dejonckheere, J., van der Vorst, E., & Schäuble, B. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.600333 · Cited by 38
“J. Berwaerts is an employee of Johnson & Johnson Pharmaceutical reported previously in trials in adults with OROS MPH (Biederman et al. 2006, 2007; Medori et al. 2008; Adler et al. 2009).”
Adler, L. A., Alperin, S., Leon, T., & Faraone, S. V. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0121 · Cited by 28
Metadata
- Authors
- Biederman, J., Mick, E. O., Surman, C., Doyle, R., Hammerness, P., Michel, E., Martin, J., & Spencer, T. J.
- Venue
- BMC Psychiatry
- Published
- 2007-09-14
- Volume
- 7
- Issue
- 1
- Pages
- 49-49
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2101603987
- Cited by
- 37
- References
- 9
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. https://app.cochat.ai/papers/10.1186/1471-244x-7-49
- The paper
- Biederman, J., Mick, E. O., Surman, C., Doyle, R., Hammerness, P., Michel, E., Martin, J., & Spencer, T. J. (2007). Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. https://doi.org/10.1186/1471-244x-7-49
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.